Home >> Research Area >>Tyrosine Kinase/Adaptors>>c-RET>> Amuvatinib (MP-470, HPK 56)

Amuvatinib (MP-470, HPK 56)

Tyrosine kinase inhibitor CAS# 850879-09-3

Amuvatinib (MP-470, HPK 56)

Catalog No. BCC2258----Order now to get a substantial discount!

Product Name & Size Price Stock
Amuvatinib (MP-470, HPK 56): 5mg $230 In Stock
Amuvatinib (MP-470, HPK 56): 10mg Please Inquire In Stock
Amuvatinib (MP-470, HPK 56): 20mg Please Inquire Please Inquire
Amuvatinib (MP-470, HPK 56): 50mg Please Inquire Please Inquire
Amuvatinib (MP-470, HPK 56): 100mg Please Inquire Please Inquire
Amuvatinib (MP-470, HPK 56): 200mg Please Inquire Please Inquire
Amuvatinib (MP-470, HPK 56): 500mg Please Inquire Please Inquire
Amuvatinib (MP-470, HPK 56): 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Amuvatinib (MP-470, HPK 56)

Number of papers citing our products

Chemical structure

Amuvatinib (MP-470, HPK 56)

3D structure

Chemical Properties of Amuvatinib (MP-470, HPK 56)

Cas No. 850879-09-3 SDF Download SDF
PubChem ID 11282283 Appearance Powder
Formula C23H21N5O3S M.Wt 447.51
Type of Compound N/A Storage Desiccate at -20°C
Synonyms MP470; HPK 56
Solubility DMSO : 50 mg/mL (111.73 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide
SMILES C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6
Standard InChIKey FOFDIMHVKGYHRU-UHFFFAOYSA-N
Standard InChI InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Amuvatinib (MP-470, HPK 56)

DescriptionAmuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.
Targetsc-KitD816HPDGFRαV561DFlt3D835Y   
IC5010 nM40 nM81 nM    

Amuvatinib (MP-470, HPK 56) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Amuvatinib (MP-470, HPK 56) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Amuvatinib (MP-470, HPK 56)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2346 mL 11.1729 mL 22.3459 mL 44.6917 mL 55.8647 mL
5 mM 0.4469 mL 2.2346 mL 4.4692 mL 8.9383 mL 11.1729 mL
10 mM 0.2235 mL 1.1173 mL 2.2346 mL 4.4692 mL 5.5865 mL
50 mM 0.0447 mL 0.2235 mL 0.4469 mL 0.8938 mL 1.1173 mL
100 mM 0.0223 mL 0.1117 mL 0.2235 mL 0.4469 mL 0.5586 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Amuvatinib (MP-470, HPK 56)

Amuvatinib (also known as MP-470 or HPK 56), a synthetic carbothioamide, is a novel and potent tyrosine kinase inhibitor, which exerts in vitro and in vivo activities against multiple targets including mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα) and DNA repair.  Μechanisticly, amuvatinib inhibits tyrosine kinase receptor KIT through occupying its ATP binding domain (IC50 < 0.1 μM) and disrupts DNA repair through suppression of homologous recombination protein Rad51 as well as synergistic effects in combination with double stranded DNA damaging agents. Recent studies have shown that amuvatinib exhibits antitumor activity against human cancer cell lines, especially GIST-48 human cell line, in which it strongly inhibits proliferation (IC50 = 0.20 μM).

Reference

Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar, Pietro Taverna, Aram Oganesian, Amarpao Sahai, Mohammad Azab and Anthony W. Tolcher. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 71: 463-471

Gavin Choy, Rajashree Joshi-Hangal, Aram Oganesian, Gil Fine, Scott Rasmussen, Joanne Collier, James Kissling, Amarpal Sahai, Mohammad Azab and Sanjeev Redkar. Saftety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. Cancer Chemother Pharmacol (2012) 70: 183-190

Featured Products
New Products
 

Description

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.

Keywords:

Amuvatinib (MP-470, HPK 56),850879-09-3,MP470; HPK 56,Natural Products,c-RET, buy Amuvatinib (MP-470, HPK 56) , Amuvatinib (MP-470, HPK 56) supplier , purchase Amuvatinib (MP-470, HPK 56) , Amuvatinib (MP-470, HPK 56) cost , Amuvatinib (MP-470, HPK 56) manufacturer , order Amuvatinib (MP-470, HPK 56) , high purity Amuvatinib (MP-470, HPK 56)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: